Royal Bank Of Canada Clovis Oncology, Inc. Transaction History

Royal Bank Of Canada

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$1.05 - $2.85 $18,452 - $50,085	17,574 Added 3.98%	459,299 $547,000
Q2 2022 Aug 15, 2022	SELL	$0.63 - $2.96 $24,935 - $117,156	-39,580 Reduced 8.22%	441,725 $796,000
Q1 2022 May 16, 2022	SELL	$1.43 - $3.14 $25,027 - $54,956	-17,502 Reduced 3.51%	481,305 $973,000
Q4 2021 Feb 14, 2022	BUY	$2.7 - $4.76 $294,505 - $519,201	109,076 Added 27.99%	498,807 $1.35 Million
Q3 2021 Nov 15, 2021	BUY	$4.06 - $5.8 $212,082 - $302,974	52,237 Added 15.48%	389,731 $1.74 Million
Q2 2021 Aug 16, 2021	BUY	$5.02 - $7.05 $1.69 Million - $2.38 Million	337,494 New	337,494 $1.96 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.